TTY Biopharm Company Limited (TPEX:4105)
83.70
-0.40 (-0.48%)
At close: Feb 11, 2026
TTY Biopharm Company Revenue
TTY Biopharm Company had revenue of 1.82B TWD in the quarter ending September 30, 2025, with 18.68% growth. This brings the company's revenue in the last twelve months to 6.50B, up 11.61% year-over-year. In the year 2024, TTY Biopharm Company had annual revenue of 5.89B with 7.05% growth.
Revenue (ttm)
6.50B
Revenue Growth
+11.61%
P/S Ratio
3.20
Revenue / Employee
19.01M
Employees
342
Market Cap
20.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.89B | 388.31M | 7.05% |
| Dec 31, 2023 | 5.51B | 443.94M | 8.77% |
| Dec 31, 2022 | 5.06B | 526.00M | 11.60% |
| Dec 31, 2021 | 4.54B | 313.77M | 7.43% |
| Dec 31, 2020 | 4.22B | -244.47M | -5.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals | 21.10B |
| Grape King Bio | 10.40B |
| YungShin Global Holding | 8.37B |
| Standard Chemical & Pharmaceutical | 6.91B |
| Synmosa Biopharma | 6.11B |
| Formosa Laboratories | 4.90B |
| ScinoPharm Taiwan | 3.19B |
| Handa Pharmaceuticals | 1.62B |